ERBB2 and breast cancer: For instance, clinical trials have utilized non-humanized gallium-68 (68Ga)-labeled anti-erBB-2 (HER2) nanoparticles for positron emission tomography (PET) diagnosis of breast cancer, thereby presenting a challenge in the context of humanized nanoparticle application [176].